Senestech Inc Stock Price, News & Analysis

SenesTech (NASDAQ: SNES) announced significant efficacy results for its contraceptive product, ContraPest, in zoo deployments. Following its use starting in December 2021, a major U.S. zoo reported a dramatic decrease in rat populations, allowing successful breeding of endangered birds for the first time in years. ContraPest has shown up to 90% efficacy improvement over traditional pest management methods. SenesTech has expanded its zoo customer base by over 300% in the past year, presenting a multimillion-dollar growth opportunity.

SenesTech, Inc. (NASDAQ: SNES) will announce its second quarter 2022 financial results on August 11, 2022, after market close. A conference call is scheduled for the same day at 5:00 pm ET to discuss these results. The company specializes in pest control through its proprietary contraceptive product, ContraPest, aimed at managing rat populations sustainably. Details for the teleconference and live webcast are provided for interested parties. For more information, visit their website.

SenesTech, Inc. (SNES) announced that its innovative Elevate Bait System with ContraPest, the only EPA registered birth control for rats, is now available for purchase nationwide, including California. This system targets roof rats effectively, especially in agricultural settings. Since its initial launch, the system has gained rapid traction, and CEO Ken Siegel highlighted significant customer interest following approval from the California Department of Pesticide Regulation. The product aims to reduce rat populations, which can reproduce exponentially, with the potential to eliminate infestations more efficiently.

SenesTech, Inc. (SNES) has launched the Elevate Bait System, an innovative EPA-registered birth control solution for roof rats, now available for purchase in the U.S. The system is designed for deployment in elevated indoor spaces to effectively target and control rat populations. This follows successful trials, showing a 95% reduction in rat activity on poultry farms after using ContraPest. The system allows easy maintenance and has received EPA approval, except in California. This breakthrough aims to combat the rising roof rat populations causing significant property damage and health risks.

SenesTech (NASDAQ: SNES) reported a remarkable 122% increase in first-quarter 2022 sales, reaching approximately $195,000, compared to $88,000 the previous year. The launch of the Elevate Bait System™ with ContraPest is anticipated to enhance market penetration, particularly in agriculture, targeting above-ground rat infestations. Despite revenue growth, the company experienced a net loss of $(2.3) million, up from $(1.8) million in Q1 2021. Cash reserves stand at approximately $7.2 million. CEO Ken Siegel emphasized ongoing sales success and innovative market solutions.

SenesTech, Inc. (NASDAQ: SNES) will disclose its first quarter 2022 financial results on May 12, 2022, after market close. The company will hold a conference call at 5:00 pm ET the same day to discuss the results. SenesTech specializes in rodent fertility control through its product, ContraPest, aiming to reduce rat populations sustainably. For participation details, interested parties can dial (844) 308-3351 or access a live webcast on the company's investor relations website.

SenesTech, Inc. (NASDAQ: SNES) will participate in the Lytham Partners Spring 2022 Investor Conference from April 4-7, 2022. A webcast presentation will be available on April 4 at 11:00 AM ET on the company's website and can be archived for later viewing. Management will also hold virtual one-on-one meetings during the event. SenesTech specializes in rodent fertility control and offers ContraPest, the first U.S. EPA-registered contraceptive for rats, aiming to minimize pest populations sustainably.

SenesTech (NASDAQ: SNES) reported a significant increase in its 2021 revenue, reaching approximately $600,000, up 113% year-over-year. Product sales surged 123%, supported by expanded deployments of ContraPest® in various sectors, including government and wildlife preservation. The company's customer base grew by 300%. Despite a net loss of $(8.3) million, cash reserves stood at approximately $9.3 million. The recent EPA approval of the Elevate Bait System™ is expected to enhance market penetration further.

SenesTech, Inc. (NASDAQ: SNES) is set to release its financial results for the fourth quarter and fiscal year 2021, concluding on December 31, 2021, after market close on March 29, 2022. A conference call will follow at 5:00 PM ET on the same day, allowing stakeholders to review the results. The company specializes in rodent fertility control, offering ContraPest, the only EPA-registered contraceptive targeting male and female rats. This innovative solution aims to significantly reduce rat populations sustainably.